GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Millendo Therapeutics Inc (NAS:MLND) » Definitions » Quick Ratio

Millendo Therapeutics (Millendo Therapeutics) Quick Ratio : 6.39 (As of Mar. 2021)


View and export this data going back to 2012. Start your Free Trial

What is Millendo Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Millendo Therapeutics's quick ratio for the quarter that ended in Mar. 2021 was 6.39.

Millendo Therapeutics has a quick ratio of 6.39. It generally indicates good short-term financial strength.

The historical rank and industry rank for Millendo Therapeutics's Quick Ratio or its related term are showing as below:

MLND's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.515
* Ranked among companies with meaningful Quick Ratio only.

Millendo Therapeutics Quick Ratio Historical Data

The historical data trend for Millendo Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Millendo Therapeutics Quick Ratio Chart

Millendo Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.82 8.81 8.50 5.68 5.12

Millendo Therapeutics Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.76 5.36 6.47 5.12 6.39

Competitive Comparison of Millendo Therapeutics's Quick Ratio

For the Biotechnology subindustry, Millendo Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Millendo Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Millendo Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Millendo Therapeutics's Quick Ratio falls into.



Millendo Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Millendo Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Quick Ratio (A: Dec. 2020 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(40.901-0)/7.987
=5.12

Millendo Therapeutics's Quick Ratio for the quarter that ended in Mar. 2021 is calculated as

Quick Ratio (Q: Mar. 2021 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(29.394-0)/4.597
=6.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Millendo Therapeutics  (NAS:MLND) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Millendo Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Millendo Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Millendo Therapeutics (Millendo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
110 Miller Avenue, Suite 100, Ann Arbor, MI, USA, 48104
Millendo Therapeutics Inc is a biopharmaceutical company.
Executives
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Howe John P Md director C/O BB&T, P O BOX 1250, WINSTON SALEM NC 27102-1250
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Carole Nuechterlein director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Geoffrey Nichol director MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
James M. Hindman director 2525 DUPONT DRIVE, IRVINE CA 92612
Christophe Arbet-engels officer: Chief Medical Officer C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Ryan Zeidan officer: Chief Development Officer C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Julia C. Owens director, officer: President and CEO C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Tamara L Joseph officer: General Counsel and Secretary 32 GARRISON STREET, APT 50-103, BOSTON MA 02116
Arcudi Iii Louis J officer: Chief Financial Officer C/O IDERA PHARMACEUTICALS 167 SYDNEY ST, CAMBRIDGE MA 02139
Randall W Whitcomb director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Jeffery M. Brinza officer: Sec., CAO and General Counsel C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Pharis Mohideen officer: Chief Medical Officer C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451